trial

A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia

NCTId NCT03627195
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 40 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2019-03-29
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2018-06-07
Primary completion
2019-03-29
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
DSP-1349M

Sponsors

Sumitomo Pharmaceuticals AmericaLead Sponsor

Sites

1 total
Long Beach, United States

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE1
Primary Completion Date
2019-03-29
Status
COMPLETED
relationships
The graph out of here
drug
DSP-1349M
drug
lead_sponsor
Sumitomo Pharmaceuticals America
company
indication
Schizophrenia
indication
Schizophrenia
indication